NP25737 A Phase I Pharmacokinetic and Safety Study of Tocilizumab (TCZ) in Patients Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis

Sponsor: Hoffman-LaRoche, Ltd.

Location(s): United States


This study will investigate the pharmacokinetics and safety of RoActemra/Actemra (tocilizumab) in patients less than 2 years old with active systemic juvenile i diopathic arthritis. Patients will receive RoActemra/Actemra infusions every 2 w eeks. The anticipated time on study treatment is 12 weeks.